Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J. Wakefield

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Molecular Oncology|February 25, 2014
Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenograftsMonique D Topp, Lynne Hartley, Michele Cook, et al.
Therapeutic Advances in Medical Oncology|November 29, 2023
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft modelsGwo Yaw Ho, Cassandra J Vandenberg, Ratana Lim, et al.
JCO Precision Oncology|February 1, 2022
Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE StudyOlga Kondrashova, Gwo-Yaw Ho, George Au-Yeung, et al.
Nature Communications|May 28, 2020
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancerElaine Sanij, Katherine M Hannan, Jiachen Xuan, et al.
Genome Biology|January 22, 2025
MaveDB 2024: a curated community database with over seven million variant effects from multiplexed functional assaysAlan F Rubin, Jeremy Stone, Aisha Haley Bianchi, et al.
Nature Communications|September 30, 2018
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova, Monique Topp, Ksenija Nesic, et al.
British Journal of Cancer|July 8, 2026
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trialKatrin M Sjoquist, Alexander Dobrovic, Kristy P Robledo, et al.
Nature|August 16, 2023
Interferon-ε is a tumour suppressor and restricts ovarian cancerZoe R C Marks, Nicole K Campbell, Niamh E Mangan, et al.
Cancer Research|July 29, 2021
Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian CarcinomaKsenija Nesic, Olga Kondrashova, Rachel M Hurley, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
<i>BRCA1</i> secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nesic, John J Krais, Cassandra J Vandenberg, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Molecular Oncology|February 25, 2014
Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenograftsMonique D Topp, Lynne Hartley, Michele Cook, et al.
Therapeutic Advances in Medical Oncology|November 29, 2023
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft modelsGwo Yaw Ho, Cassandra J Vandenberg, Ratana Lim, et al.
JCO Precision Oncology|February 1, 2022
Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE StudyOlga Kondrashova, Gwo-Yaw Ho, George Au-Yeung, et al.
Nature Communications|May 28, 2020
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancerElaine Sanij, Katherine M Hannan, Jiachen Xuan, et al.
Genome Biology|January 22, 2025
MaveDB 2024: a curated community database with over seven million variant effects from multiplexed functional assaysAlan F Rubin, Jeremy Stone, Aisha Haley Bianchi, et al.
Nature Communications|September 30, 2018
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova, Monique Topp, Ksenija Nesic, et al.
British Journal of Cancer|July 8, 2026
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trialKatrin M Sjoquist, Alexander Dobrovic, Kristy P Robledo, et al.
Nature|August 16, 2023
Interferon-ε is a tumour suppressor and restricts ovarian cancerZoe R C Marks, Nicole K Campbell, Niamh E Mangan, et al.
Cancer Research|July 29, 2021
Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian CarcinomaKsenija Nesic, Olga Kondrashova, Rachel M Hurley, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
<i>BRCA1</i> secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nesic, John J Krais, Cassandra J Vandenberg, et al.
Pageof 7